Comment from CSNK2A1 Foundation

Summary: The CSNK2A1 Foundation, a nonprofit organization representing individuals with a rare genetic neurodevelopmental disorder, supports the Haystack Project's petition for rulemaking. They argue that the current FDA framework's reliance on traditional randomized controlled trials creates barriers for rare diseases and advocate for a disease-contextual framework that utilizes patient-informed endpoints and alternative study designs.